INVESTOR UPDATE SEPTEMBER 2007 by dib16550

VIEWS: 6 PAGES: 2

									                                                   INVESTOR UPDATE: SEPTEMBER 2007




                                                    HIGHLIGHTS IN THIS ISSUE
          COLLTECH’S DISTRIBUTORS SOW THE SEEDS AND BEGIN TO REAP THE REWARDS
          INDIA A BUZZ WITH OVICOLL®
          COLLTECH HITS BIG TIME MARKETS WITH AUSTRALIAN GOVERNMENT SUPPORT
          RESEARCH AND MEDICAL COLLAGENS ON TARGET
          FAT LOSS MAY PROVE HUGE GAIN FOR COLLTECH
          GET TO KNOW THE TEAM – YOUR CHIEF SCIENTIST IN FOCUS

                                                     MARKETING AND SALES
OVICOLL® COSMETIC                    CollTech has received confirmation from its distributors in Korea, Taiwan and Thailand
PRODUCTS TO                          that cosmetic manufacturer customers have successfully formulated and product
TARGET 100 MILLION                   tested with OVICOLL®. These cosmetic products containing OVICOLL® will enter
CONSUMERS                            marketing/product launch phase through major retailers in these markets in the last
                                     quarter of this calendar year. CollTech expects an up lift in OVICOLL® sales to support
                                     these product launches and production of the products.
                                     This follows Rose Crown Australia’s announcement (one of CollTech’s first customers)
                                     that they are expanding their product line containing OVICOLL® and further expanding
                                     their product reach by entering the French and US markets.
DYNAMIC INDIAN                       During the last week of August, members of the CollTech sales team visited the Indian
MARKET HUNGRY FOR                    market. The result …. well an immediate coup for the company. CollTech is in
OVICOLL®                             discussion with two of India’s most respected and successful cosmetic distributors and
                                     manufacturers and will announce the partners as soon as formal agreements are
                                     finalised.
                                     The CollTech team visited major Indian producers such as CavinCare Limited (see
                                     insert picture left) further raising CollTech’s expectations within the Indian market.
                                     These manufacturers immediately undertook to take samples of OVICOLL® and
                                     formulate/product test thus expediting the product development phase. Before sales
                                     commence, CollTech must clear OVICOLL® for importation into India (due to India’s
                                     unique importation requirements for collagen) and is undertaking this program in
                                     parallel with these initial marketing and sales activities.
EUROPE AND USA IN                    As part of its scheduled marketing and sales activities for calendar year 2007,
COLLTECH’S LINE OF                   CollTech will be undertaking a program of distributor selection and cosmetic
SIGHT                                manufacturer visits/discussions during September and October within Europe (U.K.,
                                     France, Italy, Germany and Spain) and the USA (including exhibiting at the key
                                     Cosmetic Suppliers Day conference in Los Angeles). These strategic marketing and
                                     sales activities coincide with certain promotional activities undertaken by Austrade.
                                     CollTech will be supported by Austrade through these promotional activities and in
                                     meetings with leading cosmetic manufacturers and retailers.




CollTech Australia Ltd ABN 24 094 515 992                 P +618 9426 3900 F +618 9426 3909 W www.colltech.com.au E investors@colltech.com.au
G/ 76 Kings Park Rd West Perth WA 6005 Australia                    Sales +618 9426 3999 Freecall +800 COLLTECH Mon-Fri 8:30-5:00 GMT +8:00
PO Box 1264 West Perth WA 6872 Australia                                     ®Registered trademark of CollTech Australia Ltd│0709 Investor Update
                               Investor Update                                                                 Issued March 2007| Page 2 of 2



                                                   RESEARCH AND DEVELOPMENT
ON TARGET - UPDATE                   CollTech is on target to release its Research grade collagen in November 2007. This
                                     product is aimed at the research market where collagens are used extensively in the
                                     study of cell behaviour and interaction. This sterile product has been well received by
                                     the independent scientists who have tested it and others are interested in using it as a
                                     prototype to initiate development of biomedical devices such as collagen membranes.
                                     CollTech has developed its regulatory strategy for biomedical collagen with                              the
                                     assistance of international consultants which has focussed the efforts to progress                      this
                                     material. International standards have been applied to direct characterisation of                       our
                                     collagen as an implantable material and CollTech is well over half way through                          this
                                     characterisation process with no significant hurdles encountered to date.
LOW FAT THE KEY                      In January this year, the first shipment of biomaterial was sent to a large sausage
                                     casing manufacturer for trials. The material was shipped under a material transfer
                                     agreement (MTA) and was well received by the customer and initial trials were
                                     performed.
                                     Subsequently during this trial phase further work was undertaken to increase the yield
                                     and customer satisfaction of the end product from the sheep skins. This work
                                     discovered that the skins of different breeds of sheep contain varying fat levels which
                                     is an important component of collagen production in the food industry and specifically
                                     for sausage casing manufacturers. This work should lead to a greater uptake of our
                                     sheep skins by our large sausage casing partner in the US. CollTech who owns the IP
                                     and will receive a royalty for the shipments is not involved in the process. Product is
                                     shipped directly from the abattoir with CollTech’s input into the technique. This trial is
                                     continuing and CollTech will update investors as more information is received.

                                                       COLLTECH IN FOCUS
DR. DEBORAH COOPER                   Appointed on the 28th November 2005, Dr Deborah Cooper has become an integral
    BSc(Hons) MSc PhD                part of the CollTech team and instrumental in the development, production and launch
                                     of our OVICOLL® range. In January 2007, Deborah was appointed Acting General
                                     Manager of CollTech.
                                     Dr Cooper has more than fifteen years R&D experience in biotech and academia,
                                     including clinical manufacturing, regulatory affairs and Quality Assurance. She has
                                     previously worked for tissue engineering companies such as Clinical Cell Culture (C3)
                                     and Verigen Australia (Genzyme subsidiary). Dr Cooper holds a Bachelor of Science
                                     awarded with Honours from London University, a Master of Science in Immunology
                                     from Birmingham University and a PhD in cellular immunology from Cambridge
                                     University.
                                     Apart from refining our current OVICOLL® cosmetic range and leading the
                                     development of our next generation research and medical grade products, Deborah
                                     enjoys the theatre and is a keen dancer. But it is her passion for CollTech, collagen
                                     and the drive to be the best in her field and an inspirational leader that sets her apart
                                     from others.

                                                             CONTACT
CONTACT                              If you would like to know about our naturally sourced and purified collagen and its
                                     many uses visit ‘www.colltech.com.au’. Alternatively for investor relations enquiries
                                     please contact: Glen Brune Company Secretary and CFO on +61 8 9426 3900.




CollTech Australia Ltd ABN 24 094 515 992                  P +618 9426 3900 F +618 9426 3909 W www.colltech.com.au E investors@colltech.com.au
G/ 76 Kings Park Rd West Perth WA 6005 Australia                     Sales +618 9426 3999 Freecall +800 COLLTECH Mon-Fri 8:30-5:00 GMT +8:00
PO Box 1264 West Perth WA 6872 Australia                                      ®Registered trademark of CollTech Australia Ltd 0709 Investor Update

								
To top